Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Spero Therapeutics, Inc. (SPRO) reported a Q3 loss of $0.32 per share, missing the Zacks Consensus Estimate of a $0.27 loss. This is a significant decline from the $0.02 earnings per share reported a year ago.
November 15, 2024 | 12:00 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Spero Therapeutics reported a larger-than-expected Q3 loss of $0.32 per share, missing the consensus estimate of a $0.27 loss. This marks a significant decline from the previous year's earnings of $0.02 per share.
The reported loss of $0.32 per share is worse than the expected loss of $0.27, indicating a negative surprise for investors. The comparison to last year's earnings of $0.02 per share highlights a significant downturn in performance, likely leading to a negative short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100